certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
== Further reading == Dean L (2012). "Omeprazole Therapy and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520353. Bookshelf ID: NBK100895.
Bean chips are chips prepared using beans as a primary ingredient. Bean chips have been described as being higher in fiber and protein compared to corn and potato chips. Bean chips may be prepared from a variety of bean types and rice, such as brown rice, pinto beans, black beans, and white beans. Some bean chips are prepared using green beans. They may be prepared from a bean dough that is steamed, sliced, and fried. They may be consumed as a snack food and may be accompanied by various dips.
== Missile Impact Location System == From 1958 through 1960 the United States installed the Missile Impact Location System (MILS) in the Navy-managed Pacific Missile Range, later the Air Force–managed Western Range, to localize the splashdowns of test missile nose cones. MILS was developed and installed by the same entities that had completed the first phase of the Atlantic and U.S. West Coast SOSUS systems. A MILS installation, consisting of both a target array for precision location and a broad ocean area system for good positions outside the target area, was installed at Eniwetok as part of the system supporting intercontinental ballistic missile (ICBM) tests. Other Pacific MILS shore terminals were at the Marine Corps Air Station Kaneohe Bay supporting intermediate-range ballistic missile (IRBM) tests with impact areas northeast of Hawaii and the other ICBM test support systems at Midway Island and Wake Island.
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that in humans is encoded by the ERAP1 gene. This M1 zinc aminopeptidase is involved in the antigen processing and presentation pathway. ERAP1 is mainly located in the endoplasmic reticulum (ER), where it trims peptides at their N-terminus, adapting them for presentation by MHC class I molecules (MHC-I).
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
Sources: en.wikipedia.org
The president of the Republic of the Union of Myanmar (Burmese: နိုင်ငံတော်သမ္မတ, MLCTS: nuing ngam tau samma.ta., lit. 'President of the State') is the head of state and head of government of Myanmar. The president chairs the National Defence and Security Council and leads the Union Government (Cabinet), the executive branch of the Myanmar government. The presidency was established in 1948, when Burma gained its independence from the British Empire. During this period, the president was the ceremonial head of state while prime minister is the actual head of government. The presidency was abolished following the 1962 coup d'etat, when Ne Win assumed the powers of both head of state and head of government as the Chairman of the Revolutionary Council and the Revolutionary Government. The 1974 Constitution reintroduced the presidency, to be held by the Chairman of the Council of State. The 1988 coup d'etat again led to the presidency's abolishment, with the Chairman of the State Law and Order Restoration Council (reconstituted in 1997 as the State Peace and Development Council) assuming the functions of the head of state. The 2008 Constitution introduced a presidential system, where the president is both the head of state and government. Thein Sein assumed the presidency in 2011. After the 2015 election, the extraconstitutional post of State Counsellor of Myanmar was created for Aung San Suu Kyi, the leader of the majority party, the National League for Democracy, because she was ineligible for the presidency.
== Other uses == Gabriel Richard High School, a private high school in Michigan Golden Retriever, a dog breed Grain (unit) (gr), an amount of mass Gwoyeu Romatzyh, a system of romanization for Chinese
== Notes == "EMDB-1067: Ribosomal 80S-eEF2-sordarin complex from S. cerevisiae - EM Navigator". emnavi.protein.osaka-u.ac.jp. Retrieved 2009-08-06.{{cite web}}: CS1 maint: deprecated archival service (link) Giavalisco P, Wilson D, Kreitler T, et al. (March 2005). "High heterogeneity within the ribosomal proteins of the Arabidopsis thaliana 80S ribosome". Plant Mol. Biol. 57 (4): 577–591. Bibcode:2005PMolB..57..577G. doi:10.1007/s11103-005-0699-3. hdl:11858/00-001M-0000-0010-86C6-1. PMID 15821981. S2CID 14500573. "Ribosomes". www.cs.stedwards.edu. Archived from the original on 2009-03-20. Retrieved 2009-08-06.
A 2017 analysis in Newsweek found that 12% of those who voted for Sanders in the Democratic primary voted for Trump in the general election, a lower proportion than that of Clinton supporters in 2008 who voted for John McCain.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.